Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 30233G209 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Janus Henderson Group Ltd. 13G | 10.9% |
9/8/2026
Event 8/31/2026
|
||
|
Cormorant Asset Management, LP
13G/A
|
8.4% |
8/14/2026
Event 6/30/2026
|
||
| Cormorant Asset Management, LP | 8.4% | |||
| Bihua Chen | 8.4% | |||
|
Federated Hermes, Inc.
13G/A
|
8.0% |
10/7/2026
Event 9/30/2026
|
||
| Federated Hermes, Inc. | 8.0% | |||
| Voting Shares Irrevocable Trust | 8.0% | |||
| Thomas R. Donahue | 8.0% | |||
| Ann C. Donahue | 8.0% | |||
| J. Christopher Donahue | 8.0% | |||
| BlackRock, Inc. 13G/A | 7.7% |
7/28/2026
Event 6/30/2026
|
||
|
Franklin Resources, Inc.
13G/A
|
6.1% |
1/27/2025
Event 12/31/2024
|
||
| Franklin Resources, Inc. | 6.1% | |||
| Charles B. Johnson | 0% | |||
| Rupert H. Johnson, Jr. | 0% | |||
| Franklin Advisers, Inc. | 6.0% | |||
|
Adage Capital Management, L.P.
13G
|
5.7% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 5.7% | |||
| Robert Atchinson | 5.7% | |||
| Phillip Gross | 5.7% | |||
|
Commodore Capital LP
13G
|
5.1% |
6/3/2026
Event 5/27/2026
|
||
| Commodore Capital LP | 5.1% | |||
| Commodore Capital Master LP | 5.1% | |||
| Robert Egen Atkinson | 5.1% | |||
| Michael Kramarz | 5.1% | |||
| Vanguard Capital Management LLC 13G | 5.0% |
7/31/2026
Event 6/30/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
RA Capital Management, L.P.
13G/A
|
4.7% |
2/14/2025
Event 12/31/2024
|
||
| RA Capital Management, L.P. | 4.7% | |||
| Peter Kolchinsky | 4.7% | |||
| Rajeev Shah | 4.7% | |||
| RA Capital Healthcare Fund, L.P. | 4.7% | |||
|
TCG Crossover GP II, LLC
13G/A
|
4.3% |
2/17/2026
Event 12/31/2025
|
||
| TCG Crossover GP II, LLC | 4.3% | |||
| TCG Crossover Fund II, L.P. | 4.3% | |||
| Chen Yu | 4.3% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
3.8% |
5/15/2026
Event 3/31/2026
|
||
| Paradigm BioCapital Advisors LP | 3.8% | |||
| Paradigm BioCapital Advisors GP LLC | 3.8% | |||
| Senai Asefaw, M.D. | 3.8% | |||
| Paradigm BioCapital International Fund Ltd. | 3.3% | |||
| Vanguard Group Inc 13G/A | 0% |
3/26/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 4.21 k | $13.8 k |
| 2026 Q2 | 209 | 94.3 M | $1.43 B |
| 2026 Q1 | 206 | 90.1 M | $1.16 B |
| 2025 Q4 | 178 | 83.6 M | $1.53 B |
| 2025 Q3 | 164 | 69.9 M | $996 M |
| 2025 Q2 | 154 | 69.1 M | $651 M |
| 2025 Q1 | 162 | 74.1 M | $402 M |
| 2024 Q4 | 154 | 74.4 M | $553 M |
| 2024 Q3 | 148 | 58.9 M | $479 M |
| 2024 Q2 | 167 | 61.0 M | $531 M |
| 2024 Q1 | 182 | 58.0 M | $1.20 B |
| 2023 Q4 | 163 | 52.1 M | $1.20 B |
| 2023 Q3 | 111 | 33.7 M | $270 M |
| 2023 Q2 | 88 | 31.6 M | $275 M |
| 2023 Q1 | 71 | 29.1 M | $85.6 M |
| 2022 Q4 | 82 | 29.8 M | $104 M |
| 2022 Q3 | 92 | 31.5 M | $250 M |
| 2022 Q2 | 88 | 30.2 M | $238 M |
| 2022 Q1 | 89 | 30.4 M | $370 M |
| 2021 Q4 | 99 | 29.8 M | $365 M |
| 2021 Q3 | 70 | 22.1 M | $231 M |
| 2021 Q2 | 68 | 20.7 M | $186 M |
| 2021 Q1 | 67 | 19.6 M | $200 M |
| 2020 Q4 | 35 | 7.70 M | $50.7 M |